EMA Recommends Extension of Indications for Pirtobrutinib By Ogkologos - April 24, 2025 657 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma MOST POPULAR 癌症治疗期间如何保证日常活动的安全和独立执行 March 16, 2021 Inequalities cause 2,000 extra cancer cases in Wales June 8, 2023 Aromatase inhibitors cut breast cancer recurrence in younger patients February 11, 2022 Teen Quarterback Scores 8 Touchdowns A Day After His Mom Dies... November 20, 2021 Load more HOT NEWS Same Breast Cancer, Same Place, Same Treatment. This Mother and Daughter... Working to Make Cancer Clinical Trials More Inclusive: A Q&A With... Tackling under-representation of Black data scientists in cancer research Having Cancer as a Young Adult Put Me on a Path...
